

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)


Applicant(s): DeSimone et al.

Docket No.

CGI-0006

Serial No.
10/658,121Filing Date
September 9, 2003Examiner
NYAGroup Art Unit
1614

Invention: 6-Aryl-Imidazo[1,2-a]Pyrazin-8-Ylamines, Method Of Making, And Method Of Use Thereof

I hereby certify that this Trans. of IDS (2 pgs), 1449 (3 pgs), Cited Art (16 refs), Cert of Mail, postcard
*(Identify type of correspondence)*is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The
Commissioner of Patents and Trademarks, Washington, D.C. 20231-0001 on January 20, 2004
*(Date)*Laura J. Nolan*(Typed or Printed Name of Person Mailing Correspondence)*

A handwritten signature in black ink that reads "Laura J. Nolan".

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
CGI-0006

In Re Application Of: **DeSimone et al.**

Serial No.
10/658,121

Filing Date
September 9, 2003

Examiner
NYA

Group Art Unit
1614

Title: **6-Aryl Imidazo[1,2-a]Pyrazin-8-Ylamines, Method Of Making, And Method Of Use Thereof**



Address to:
**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 CGI-0006

In Re Application: DeSimone et al.


Serial No.
 10/658,121

Filing Date
 September 9, 2003

Examiner
 NYA

Group Art Unit
 1614

6-Aryl Imidazo[1,2-a]Pyrazin-8-Ylamines, Method Of Making, And Method Of Use Thereof



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below.
- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on January 20, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


 Signature of Person Mailing Correspondence

Laura J. Nolan

 Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


 Signature

Leah M. Reimer

Reg. No. 39,341

Customer No. 23,413

(860) 286-2929


Dated: January 20, 2004

CC:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CGI-0006

Application Number

10/658,121

Applicant(s)

DeSimone, et al.

Filing Date

September 9, 2003

Group Art Unit

1614

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Stenberg, Kaj A.E. et al. "KinMutBase, a database of human disease-causing protein kinase mutations", Nucleic Acids Research 2000, Vol. 28, pp. 369-371

Vitse, O. et al., "New Imidazo[1,2-a]pyrazine Derivatives with Bronchodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities", Bioorganic & Medicinal Chemistry, 1999, Vol. 7, pgs. 1059-1065

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.